Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Want to see STRO full AI Analyst Report?
Top Page
Sutro Biopharma
(NASDAQ:STRO)
Select Model
Select Model
Rating:45Neutral
Price Target:
$25.00
▼(-20.76% Downside)
Action:Reiterated
Date:06/09/26
The score is held down primarily by weak financial performance—large losses, heavy cash burn, and negative equity—indicating elevated financing risk. Technicals also point to a pressured downtrend (below key moving averages with negative MACD). Corporate events provide a modest offset via financing/runway improvements and pipeline progress, while valuation remains difficult to support due to negative earnings and no dividend.
Positive Factors
Proprietary cell-free protein synthesis platform (XpressCF)
Sutro’s proprietary cell-free protein synthesis platform (XpressCF) is a durable competitive asset that enables rapid, precise protein engineering and production. This platform supports both internal pipeline acceleration and partner collaborations, creating recurring partnership revenue and differentiation in ADC and engineered biologics markets over years.
Negative Factors
Large, persistent negative operating cash flow
Sustained negative operating cash flow (~-$151.6M TTM) and free cash flow (~-$152.1M TTM) reflect ongoing high burn from R&D and operations. This persistent cash consumption creates continual financing needs, increases dilution risk over time, and limits optionality for opportunistic investments or partnerships absent further funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cell-free protein synthesis platform (XpressCF)
Sutro’s proprietary cell-free protein synthesis platform (XpressCF) is a durable competitive asset that enables rapid, precise protein engineering and production. This platform supports both internal pipeline acceleration and partner collaborations, creating recurring partnership revenue and differentiation in ADC and engineered biologics markets over years.
Read all positive factors
Sutro Biopharma (STRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$432.32M
Dividend YieldN/A
Average Volume (3M)987.85K
Price to Earnings (P/E)―
Beta (1Y)3.58
Revenue Growth49.94%
EPS Growth44.76%
CountryUS
Employees269
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-307.72
Shares Outstanding16,570,438
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit1.92
Enterprise Value/Ebitda-1.77
Forecast
1Y Price Target
$48.44Price Target Upside53.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-8.99
Revenue Forecast (FY)$41.37M
Sutro Biopharma Business Overview & Revenue Model
Company Description
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions lik...
How the Company Makes Money
Sutro primarily generates revenue through collaboration and licensing arrangements rather than product sales, because it is a clinical-stage company and does not have null. Key revenue streams generally include (1) upfront payments received when e...
Sutro Biopharma Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
31
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.61M | 102.48M | 62.04M | 153.73M | 67.77M | 61.88M |
| Gross Profit | 98.33M | 95.16M | 54.83M | 146.91M | 59.48M | 52.11M |
| EBITDA | -106.70M | -97.63M | -180.45M | -67.92M | -105.07M | -97.56M |
| Net Income | -153.60M | -191.09M | -227.46M | -106.79M | -119.20M | -105.54M |
Balance Sheet | ||||||
| Total Assets | 241.99M | 173.83M | 387.21M | 470.74M | 406.94M | 341.41M |
| Cash, Cash Equivalents and Short-Term Investments | 202.56M | 141.43M | 316.89M | 375.62M | 334.36M | 197.94M |
| Total Debt | 13.63M | 15.67M | 23.15M | 33.63M | 55.02M | 57.37M |
| Total Liabilities | 308.88M | 306.28M | 342.61M | 321.09M | 189.90M | 88.84M |
| Stockholders Equity | -66.89M | -132.45M | 44.60M | 149.65M | 217.05M | 252.56M |
Cash Flow | ||||||
| Free Cash Flow | -152.14M | -178.93M | -194.64M | -115.93M | -4.31M | -97.00M |
| Operating Cash Flow | -151.61M | -177.23M | -191.54M | -111.62M | 3.55M | -81.68M |
| Investing Cash Flow | 16.01M | 45.01M | 218.51M | -3.92M | -35.02M | -97.31M |
| Financing Cash Flow | 103.05M | 44.00K | 94.05M | 137.55M | 48.31M | 3.26M |
Sutro Biopharma Technical Analysis
Negative
31.55
Price Trends
31.34
Negative
25.17
Positive
17.36
Positive
Market Momentum
-2.00
Positive
39.66
Neutral
29.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STRO, the sentiment is Negative. The current price of 31.55 is above the 20-day moving average (MA) of 30.66, above the 50-day MA of 31.34, and above the 200-day MA of 17.36, indicating a neutral trend. The MACD of -2.00 indicates Positive momentum. The RSI at 39.66 is Neutral, neither overbought nor oversold. The STOCH value of 29.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STRO.
Sutro Biopharma Risk Analysis
Sutro Biopharma disclosed 78 risk factors in its most recent earnings report. Sutro Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sutro Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $32.17M | -0.77 | -170.86% | ― | -100.00% | 13.12% | |
47 Neutral | $20.83M | -0.69 | -136.08% | ― | -77.56% | -50.38% | |
47 Neutral | $68.34M | -0.72 | -80.35% | ― | ― | 27.27% | |
45 Neutral | $432.32M | -0.02 | 275.30% | ― | 49.94% | 44.76% | |
40 Underperform | $17.74M | -0.32 | -208.23% | ― | -100.00% | 26.30% |
* Healthcare Sector Average
STRO
Sutro Biopharma
26.09
17.82
215.55%
CRVO
CervoMed
2.25
-5.22
-69.88%
ACET
Adicet Bio
7.31
-5.25
-41.78%
INMB
Inmune Bio
1.21
-6.88
-85.04%
HOWL
Werewolf Therapeutics
0.37
-0.87
-70.33%
Sutro Biopharma Corporate Events
Executive/Board ChangesShareholder Meetings
Sutro Biopharma Shareholders Back Board, Pay and Auditor
Positive
Jun 8, 2026
On June 5, 2026, Sutro Biopharma held its 2026 Annual Meeting of Stockholders, where shareholders elected three Class II directors, Jane Chung, Connie Matsui, and James Panek, each to serve a three-year term ending at the 2029 Annual Meeting. The ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Sutro Biopharma Ends ATM Agreement After 2025 Results
Positive
Mar 23, 2026
On March 23, 2026, Sutro Biopharma reported full-year 2025 results and announced the mutual termination of its at-the-market equity sales agreement with Jefferies, closing a potential source of incremental share issuance. The company highlighted p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.